In the study of Bund et al. (2006), 18 out of 18 CLL patient samples were SLAMF3/CD229-positive by flow cytometry, with a median of 63% positive CLL B cells [53]. This evidence concerns the gene LY9 and B-cell chronic lymphocytic leukemia.